The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma.
 
Paolo Antonio Ascierto
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
Oliver Bechter
Consulting or Advisory Role - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Roche
 
Pascal Wolter
No Relationships to Disclose
 
Celeste Lebbe
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Elena Elez
No Relationships to Disclose
 
Wilson H. Miller
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Research Funding - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; MedImmune; Merck; MethylGene; Novartis; Roche
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; MERCK; Novartis; Pierre Fabre; Roche/Genentech
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche/Genentech
 
Aurelius Gabriel Omlin
Consulting or Advisory Role - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - Janssen (Inst); Teva (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen; Sanofi
 
Salvatore Siena
Consulting or Advisory Role - Amgen; Bayer; Lilly; Merck; Roche; Sanofi
Research Funding - Bayer (Inst)
 
Emiliano Calvo
Consulting or Advisory Role - Astellas Pharma; GlaxoSmithKline; Lilly/ImClone; Nanobiotix; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Novartis
Research Funding - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Janssen Oncology; Lilly; Merck; Millennium; Nektar; Novartis; OncoMed; Pfizer; PharmaMar; PsiOxus Therapeutics; Puma Biotechnology; Roche/Genentech; Sanofi; Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - Lilly; Novartis; PsiOxus Therapeutics
Other Relationship - Pierre Fabre
 
Mike Pickard
Employment - Array BioPharma
Stock and Other Ownership Interests - Array BioPharma
Consulting or Advisory Role - Mitomics
 
Ashwin Gollerkeri
Employment - Array BioPharma
Stock and Other Ownership Interests - Array BioPharma
Patents, Royalties, Other Intellectual Property - Yale University (I)
 
Lance Wollenberg
Employment - Array BioPharma
Stock and Other Ownership Interests - Array BioPharma
 
Caroline Germa
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda
Research Funding - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda